Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 10/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 2/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 4/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5655803 | 1.00 | MIF (0.35) | MIFHDAC6F10ITGB3ITGA2B | |
| SCHEMBL5655313 | 0.88 | MIF (0.37) | MIFHDAC6ITGB3ITGA2BRAB9A | |
| SCHEMBL5834526 | 0.81 | MAOA (0.45) | F10ITGB3ITGA2B | |
| SCHEMBL5655795 | 0.77 | MIF (0.33) | MIFHDAC6F10ITGB3ITGA2B | |
| SCHEMBL14344986 | 0.75 | MIF (0.34) | MIFHDAC6NAMPT | |
| SCHEMBL5834248 | 0.74 | MAOA (0.49) | F10 | |
| SCHEMBL5833366 | 0.72 | MAOA (0.57) | F10 | |
| SCHEMBL5945090 | 0.72 | CYP2E1 (0.55) | F10 | |
| Hydrochloric Acid SCHEMBL5655923 | 0.72 | HTR2C (0.37) | MIFHDAC6RAB9A | |
| Hydrochloric Acid SCHEMBL5655920 | 0.72 | HTR2C (0.37) | MIFHDAC6RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070281916-A1 | Substituted isoxazolines and their use as antibacterial agents | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | US | disclosed |
| US-7081538-B1 | Substituted isoxazolines and their use as antibacterial agents | ASTRAZENECA AB (SE) | 2006-07-25 | — | — | US | disclosed |
| EP-1242416-B1 | SUBSTITUTED ISOXAZOLINES AND THEIR USE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2005-04-13 | — | — | EP | disclosed |
| EP-1242416-A1 | SUBSTITUTED ISOXAZOLINES AND THEIR USE AS ANTIBACTERIAL AGENTS | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001040222-A1 | SUBSTITUTED ISOXAZOLINES AND THEIR USE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281916-A1 | Substituted isoxazolines and their use as antibacterial agents | CYP2S1, CYP3A7, CYP3A5 | MIF 4704/4885HDAC6 504/4885F10 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.